Date: 07 May 2008
New Insights into the Roles of Fibroblast Growth Factor 23
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Fibroblast growth factor 23 (FGF23) is expressed primarily in skeletal tissues including osteoblasts/osteocytes and acts as a hormone regulating phosphate and vitamin D homeostasis. An excess of active FGF23 in the circulation causes multiple anomalies seen in phosphaturic diseases including rickets/osteomalacia, consistent with some but not all of the phenotypic anomalies seen in FGF23 deficient mice. FGF23 is targeted to kidney and negatively regulates activity/expression of the type II sodium-phosphate cotransporter (NPT2) as well as 25-hydroxy vitamin D-1α-hydroxylase in proximal tubular cells. Recently, teeth have been identified as a possible second principle source of FGF23. Further, both the parathyroid and bone also appear to be functional targets of FGF23: the polypeptide decreases parathyroid hormone (PTH) production and suppresses bone formation in vitro, suggesting a new dimension of FGF23 biology in development and homeostasis. In contrast to other FGF family members, FGF23 requires Klotho, a senescence-related type I membrane protein, for its specific signaling in target organs. However, Klotho expression has not yet been confirmed in skeletal tissues. Nevertheless, similarly to FGF2, FGF23 promotes FGFR1 phosphorylation whose signaling is involved in the negative regulation of bone formation. 1α,25-dihydroxyvitamin D3 (1,25(OH)2D) is a potent regulator of FGF23 expression, closely correlated with its inhibitory effect on matrix mineralization. The cleaved extracellular domain of Klotho is known to act as a circulating factor. Therefore, FGF23 may be able to act on multiple tissues including skeletal tissues as a pleiotropic factor, coordinately with or without 1,25(OH)2D and PTH.
Clinical Reviews in Bone and Mineral Metabolism
Favus MJ, Bushinsky DA, Lemann Jr J. Regulation of calcium, magnesium, and phosphate metabolism. In: Favus MJ, editor. Primer on the metobolic bone diseases and disorders of mineral metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research; 2006.
Hattenhauer O, Traebert M, Murer H, Biber J. Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake. Am J Physiol. 1999;277(4 Pt 1):G756–62.PubMed
Brown EM, Juppner H. Parathyroid hormone: synthesis, secretion, and action. In: Favus MJ, editor. Primer on the metobolic bone diseases and disorders of mineral metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research; 2006.
The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345–8.CrossRef
Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest. 2003;112(5):785–94.PubMed
Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112(5):683–92.PubMed
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–8.PubMed
Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the α(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145(7):3087–94.PubMedCrossRef
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117(12):4003–8.PubMed
Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008; [Epub ahead of print].
Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, et al. 1α,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol. 2005;289(6):G1036–42.PubMedCrossRef
- New Insights into the Roles of Fibroblast Growth Factor 23
Clinical Reviews in Bone and Mineral Metabolism
Volume 6, Issue 1-2 , pp 17-23
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press Inc
- Additional Links
- Phosphate homeostasis
- Bone formation
- Industry Sectors